Amundi’s Viridian Therapeutics VRDN Stock Holding History

Amundi’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-83	Closed	-$1.05K	–	2177
2025 Q1	$1.05K	Buy	83 +5	+6%	+$85	﹤0.01%	2030
2024 Q4	$1.49K	Buy	+78	New	+$1.7K	﹤0.01%	2006

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Amundi's VRDN Position: Q2 2025 in Review

Amundi sold out of Viridian Therapeutics (VRDN) in Q2 2025, closing a stake of 83 shares — an estimated $1.05K sold.

Amundi first reported a position in VRDN in Q4 2024 and held it in 2 quarters. The position peaked at $1.49K in Q4 2024. 170 funds tracked by Wall St. Rank hold VRDN as of Q2 2025.

Amundi reported no remaining Viridian Therapeutics position as of Q2 2025 after selling out during the quarter.
Amundi sold 83 Viridian Therapeutics shares in Q2 2025, an estimated $1.05K.
Amundi first reported a position in Viridian Therapeutics in Q4 2024 and held it in 2 quarters.
Amundi's Viridian Therapeutics position peaked at $1.49K in Q4 2024.
170 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.